Karo Pharma (Cancer Project KB9520) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Karo Pharma (Cancer Project KB9520) General Information
Description
KB9520 estrogen receptor cancer drug developed for cancer treatment. The asset provides various type of cancer treatment.
Contact Information
Corporate Office
- Nybrokajen 7
- Stockholm
- Sweden
Corporate Office
- Nybrokajen 7
- Stockholm
- Sweden
Karo Pharma (Cancer Project KB9520) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Karo Pharma (Cancer Project KB9520) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Karo Pharma (Cancer Project KB9520) FAQs
-
Where is Karo Pharma (Cancer Project KB9520) headquartered?
Karo Pharma (Cancer Project KB9520) is headquartered in Stockholm, Sweden.
-
What industry is Karo Pharma (Cancer Project KB9520) in?
Karo Pharma (Cancer Project KB9520)’s primary industry is Buildings and Property.
-
Is Karo Pharma (Cancer Project KB9520) a private or public company?
Karo Pharma (Cancer Project KB9520) is a Private company.
-
What is Karo Pharma (Cancer Project KB9520)’s current revenue?
The current revenue for Karo Pharma (Cancer Project KB9520) is .
-
Who are Karo Pharma (Cancer Project KB9520)’s investors?
Karo Healthcare has invested in Karo Pharma (Cancer Project KB9520).
-
When was Karo Pharma (Cancer Project KB9520) acquired?
Karo Pharma (Cancer Project KB9520) was acquired on 24-Oct-2016.
-
Who acquired Karo Pharma (Cancer Project KB9520)?
Karo Pharma (Cancer Project KB9520) was acquired by Vivesto.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process